The Icos Alumni: Where Are They Now?
Luke Timmerman11/18/09Comments (4)Follow @ldtimmerman
(Page 7 of 9)
—Leslie Milligan, senior clinical data manager, i3StatProbe
—Rosemary Monaghan, biotechnology professional
—Susan Moon, freelance medical writer
—Robin Moore, vice president of worldwide procurement, Getty Images [Added 12/30/09]
—Amy Moro, quality assurance analyst, Quidel
—Michael Moro, senior project manager of clinical supplies, Bilcare GCS
—Steve Murdock, partner, life sciences practice leader, Allen Austin Executive Search
—Aileen Murphy, director of biometrics, Seattle Genetics [Added 12/30/09]
—Colleen Murphy, lab supply coordinator, MDRNA
—Sean O’Dea, vice president of intellectual property, 3-V Biosciences
—Joshua Odingo, director of chemistry, Infectious Disease Research Institute
—Amy Oliver, chemicals professional
—Harch Ooi, senior scientist, process chemistry, Seattle Genetics
—Mark Orme, group leader of chemistry, Acucela
—Karen Osofsky Michelson, senior manager of talent acquisition, Amazon.com
—Karen Parker, clinical trial manager, Genentech
—Leland Paul, vice president of process development, CMC Icos
—Noah Pefaur, staff scientist, Novo Nordisk
—Sissy Peterman, clinical research manager, Calistoga Pharmaceuticals
—Scott Peterson, vice president of research and development, Oncothyreon
—Tony Phan, manufacturing manager, Infectious Disease Research Institute
—Louise Pobanz, finance director, CMC Icos
—Tamara Potter, clinical research associate, Medicis Technologies
—John Pribble, vice president of medical affairs, ZymoGenetics
—Jeffrey Price, engineering technician, CMC Icos
—Mark Prudhon, clinical supply manager, Seattle Genetics
—Kamal Puri, principal scientist, head of biology, Calistoga Pharmaceuticals
—Carol Raport, senior scientist, VLST
—George Rathmann, retired
—Padma Ravikumar, senior research associate, Trubion Pharmaceuticals
—Mark Reed, director of medicinal chemistry, Treventis
—Rob Rees, senior systems engineer, CMC Icos
—Mark Rice, staff scientist, CMC Icos
—Maha Rizk, scientist
—Kathy Rogers, associate director, statistical programming, ZymoGenetics … Next Page »
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
Johnny T. Stine
11/18/09 1:48 pm
I actually loved our logo – very simple, but it just looked like fun.
When George R. was recently asked by a reporter from an Everett newspaper about building Icos into a company like Amgen….he replied “…..why would I stop there?”. With a leader like that, like George, one who inspires with energetic goals such as that mentioned – we could’ve done it. We had the tools and the ability to do just that. We had great people who’ve all proven themselves in places before and afterward…….but imagine what we could’ve done behind the hopes of a great leader like George who set that tone….a CEO who knew all of our names, someone who would talk to you like you were a valued asset, a guy that empowered us via ownership. Imagine what we could’ve done…..because that’s all we’re left to do.
By the way- Luke – I prefer Icosanoids – a play on the word eicosanoid since we were primarily an inflammation company. :-)
Luke Timmerman
11/18/09 2:04 pm
Johnny—Unfortunately, I never really got to know George very well because he had already left Icos by the time I started covering the company in 2001. But I made a point of meeting him at his home once a couple years ago when I was based in San Francisco. He wasn’t in great health, but he was still sharp and very much curious about the latest happenings in biotech.
I haven’t heard the term Icosanoids from eicosanoid, but that made me laugh this morning. It sounds like something from Star Trek. Anybody know if this was also the inspiration for the term “Immunoids” for people who used to work at Immunex?
David Miller
11/23/09 2:54 pm
Nice work, Luke. Goes to prove that even though we might lose companies through acquisition we’d really rather keep, it’s not like everything connected with the company disappears. By my eye, the “loss” of Icos created at least a half-dozen new companies and significantly strengthened a dozen or more startups. A nice silver lining.
Abby Kliphardt
3/3/10 10:19 am
Nice article…good to see where my co-workers have ended. I loved my time at ICOS and will always lament the loss of a great company that was a real family….